Talaris Therapeutics, Inc. |
10%+ Owner |
Common Stock |
3.22M |
$54.7M |
$16.99 |
May 11, 2021 |
By Longitude Venture Partners III, L.P. |
Inozyme Pharma, Inc. |
10%+ Owner |
Common Stock |
4.17M |
$14.9M |
$3.57 |
Apr 19, 2022 |
By Longitude Venture Partners III, L.P. |
Sierra Oncology, Inc. |
10%+ Owner |
Common Stock |
8.02K |
$441K |
$55.00 |
Apr 27, 2022 |
Indirect |
Talaris Therapeutics, Inc. |
10%+ Owner |
Series A-1 Preferred Stock |
0 |
|
|
May 11, 2021 |
By Longitude Venture Partners III, L.P. |
Talaris Therapeutics, Inc. |
10%+ Owner |
Series A Preferred Stock |
0 |
|
|
May 11, 2021 |
By Longitude Venture Partners III, L.P. |
Talaris Therapeutics, Inc. |
10%+ Owner |
Series B Preferred Stock |
0 |
|
|
May 11, 2021 |
By Longitude Venture Partners III, L.P. |